Anixa Biosciences is trading 6.88% up in after-hours trading at $2.95 after September 11, 2026, presentations highlighted encouraging early data from its ovarian-cancer and breast-cancer programs.

  • CEO Amit Kumar purchased 5,000 shares for $13,799 on September 10.
  • Broader markets gained roughly 0.85%-0.99%.
  • The company-specific presentation appears to be the clearest catalyst; no earnings release was identified.